Cargando…

Phase 2 Study of the Factor XI Antisense Inhibitor IONIS-FXI(Rx) in Patients With ESRD

INTRODUCTION: Patients with end-stage renal disease (ESRD) requiring hemodialysis (HD) have an increased risk of thrombotic events and bleeding. Antisense reduction of factor XI (FXI) with IONIS-FXI(Rx) is a novel strategy that may safely reduce the risk of thrombotic events. METHODS: This multicent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walsh, Michael, Bethune, Claudette, Smyth, Andrew, Tyrwhitt, Jessica, Jung, Shiangtung W., Yu, Rosie Z., Wang, Yanfeng, Geary, Richard S., Weitz, Jeffrey, Bhanot, Sanjay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820988/ https://www.ncbi.nlm.nih.gov/pubmed/35155859 http://dx.doi.org/10.1016/j.ekir.2021.11.011

Ejemplares similares

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
por: Willmann, Stefan, et al.
Publicado: (2021)

Antisense Inhibition of Angiotensinogen With IONIS-AGT-L(Rx): Results of Phase 1 and Phase 2 Studies
por: Morgan, Erin S., et al.
Publicado: (2021)

IONIS-PKK(Rx) a Novel Antisense Inhibitor of Prekallikrein and Bradykinin Production
por: Ferrone, Jason D., et al.
Publicado: (2019)

OR27-4 Placebo-Controlled and Open-Label Extension Study of a Novel Hepatic-Targeted Antisense Cimdelirsen (IONIS-GHR-LRx) Under Investigation in Acromegaly Patients
por: Bhanot, Sanjay, et al.
Publicado: (2022)

Analysis of 272 Genetic Variants in the Upgraded Interactive FXI Web Database Reveals New Insights into FXI Deficiency
por: Harris, Victoria A., et al.
Publicado: (2021)

Anticoagulant therapy in patients with congenital FXI deficiency
por: Bravo-Pérez, Carlos, et al.
Publicado: (2021)

Model‐dependent contributions of FXII and FXI to venous thrombosis in mice
por: Grover, Steven P., et al.
Publicado: (2020)

BJTJ-1837, a novel FXI activation-blocking antibody
por: He, Xugang, et al.
Publicado: (2023)

Misura del Flusso di Ioni Leggeri con l'Esperimento Spaziale AMS
por: Molino, K
Publicado: (1999)

“Familial Multiple Coagulation Factor Deficiencies of FXI and FXII in an Asymptomatic Saudi Woman”
por: Al-Ansari, Rehab Y., et al.
Publicado: (2023)

Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-L(Rx) (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
por: Coelho, Teresa, et al.
Publicado: (2021)

Improvements in the Tolerability Profile of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in Parallel with Advances in Design, Screening, and Other Methods
por: Partridge, Wesley, et al.
Publicado: (2021)

Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data
por: Viney, Nicholas J., et al.
Publicado: (2020)

Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)

Correlazioni di particelle in collisioni di ioni pesanti per l'esperimento ALICE a LHC
por: Noferini, Francesco
Publicado: (2012)

Integrated Assessment of Phase 2 Data on GalNAc(3)-Conjugated 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides
por: Baker, Brenda F., et al.
Publicado: (2023)

Lack of QT Prolongation for 2′-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects
por: Yu, Rosie Z., et al.
Publicado: (2017)

Association of FXI activity with thrombo-inflammation, extracellular matrix, lipid metabolism and apoptosis in venous thrombosis
por: Pallares Robles, Alejandro, et al.
Publicado: (2022)

Integrated Assessment of the Clinical Performance of GalNAc(3)-Conjugated 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience
por: Crooke, Stanley T., et al.
Publicado: (2019)

P1681: FXI LEVELS AS INDEPENDENT RISK FACTOR FOR THROMBOSIS/OBSTETRIC EVENTS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
por: De La Morena-Barrio, M. E., et al.
Publicado: (2022)

Predictive Dose-Based Estimation of Systemic Exposure Multiples in Mouse and Monkey Relative to Human for Antisense Oligonucleotides With 2′-O-(2-Methoxyethyl) Modifications
por: Yu, Rosie Z, et al.
Publicado: (2015)

A novel mouse whole blood thrombin generation assay sensitive to FXI- and FIX-mediated amplification of coagulation
por: Wan, Jun, et al.
Publicado: (2022)

The Effects of 2′-O-Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials
por: Crooke, Stanley T., et al.
Publicado: (2017)

Lower Mortality in Living Kidney Donors With ESRD Versus Matched Nondonors With ESRD
por: Muzaale, Abimereki D.
Publicado: (2018)

Factors XI and XII as Targets for New Anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017)

Iron status in ESRD patients
por: Wiwanitkit, V.
Publicado: (2011)

The Tragedy of Having ESRD in Mexico
por: Garcia-Garcia, Guillermo, et al.
Publicado: (2018)

Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro
por: Shi, Y., et al.
Publicado: (2021)

Rx.NET in action
por: Dresher, Tamir
Publicado: (2017)

RxJS in action
por: Daniels, Paul P, et al.
Publicado: (2017)

RxJava essentials
por: Morgillo, Ivan
Publicado: (2015)

Learning RxJava
por: Samoylov, Nick
Publicado: (2020)

Rx—The Eye of Horus
por: Walker, Clive
Publicado: (1992)

Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial
por: Mummery, Catherine J., et al.
Publicado: (2023)

Protein Nutrition and Malnutrition in CKD and ESRD
por: Zha, Yan, et al.
Publicado: (2017)

Identification of ESRD in Cardiovascular Procedural Databases
por: Charytan, David M., et al.
Publicado: (2019)

COVID-19 infection recurrence in ESRD
por: Onuigbo, Macaulay A. C.
Publicado: (2022)

Integrated Safety Assessment of 2′-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers
por: Crooke, Stanley T, et al.
Publicado: (2016)

ER network dynamics are differentially controlled by myosins XI-K, XI-C, XI-E, XI-I, XI-1, and XI-2
por: Griffing, Lawrence R., et al.
Publicado: (2014)

RxJava for Android Developers
por: Tuominen, Timo
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5nmvuppajcerbi8f88msmjm111